当前位置： SCI文献检索 > PROSTATE CANCER AND PROSTATIC DISEASES期刊下所有文献 > Performance of biopsy factors in predicting unfavorable disease in patients eligible for active surveillance according to the PRIAS criteria.

Performance of biopsy factors in predicting unfavorable disease in patients eligible for active surveillance according to the PRIAS criteria.

Abstract：

BACKGROUND:To assess the added value of biopsy factors, like maximum cancer length in a core (MCL), cumulative cancer length (CCL), cumulative length of positive cores (CLPC), percentage of cancer involvement in positive cores (CIPC) and the Prostate Cancer Research International: Active Surveillance (PRIAS) criteria in patients who underwent radical prostatectomy (RP) but eligible for active surveillance (AS). METHODS:From January 2002 to December 2007, 750 consecutive subjects underwent RP. We identified 147 (19.07%) patients who were eligible for AS based on PRIAS criteria: clinical stage T1c or T2, PSA level of ⩽ 10 ng ml(-1), Gleason score ⩽ 6, PSA-D of <0.2 ng ml(-2) and one or two positive biopsy cores. We calculated the diagnostic accuracy of biopsy factors in determining pathological confirmed unfavorable disease. Decision curve analysis (DCA) were performed. RESULTS:Of all subjects, 95 patients (66.43%) had favorable whereas 48 had (33.57%) unfavorable disease. On multivariate analyses, the inclusion of MCL, CCL, CLPC and CIPC significantly increased the accuracy of the base multivariate model in predicting unfavorable disease. The gain in predictive accuracy for MCL in a core, CCL, CLPC and CIPC ranged from 13 to 27%. The DCA shows that adding MCL, CCL, CLPC and CIPC resulted in a greater net benefit when the probability of ranges between 15 and 50%. The models can be applied at the cost of missing not more than 16.83% of unfavorable disease. CONCLUSIONS:Our findings suggested that the addition of these biopsy factors to PRIAS criteria has the potential to significantly increase the ability to detect unfavorable disease.

journal_name

Prostate Cancer Prostatic Dis

journal_title

Prostate cancer and prostatic diseases

authors

Russo GI,Castelli T,Favilla V,Reale G,Urzì D,Privitera S,Fragalà E,Cimino S,Morgia G

doi

10.1038/pcan.2015.26

subject

Has Abstract

pub_date

2015-12-01 00:00:00

pages

338-42

issue

4

eissn

1365-7852

issn

1476-5608

pii

pcan201526

journal_volume

18

pub_type

杂志文章

相关文献

PROSTATE CANCER AND PROSTATIC DISEASES文献大全
  • The effect of exercise training on cardiometabolic health in men with prostate cancer receiving androgen deprivation therapy: a systematic review and meta-analysis.

    abstract：BACKGROUND:Growing evidence suggests that men exposed to androgen deprivation therapy (ADT) have an increased risk of cardiovascular disease. While exercise has shown to attenuate some adverse effects of ADT, the effects on cardiometabolic health have not been systematically evaluated. OBJECTIVE:To evaluate the effect...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/s41391-020-00273-5

    authors： Bigaran A,Zopf E,Gardner J,La Gerche A,Murphy DG,Howden EJ,Baker MK,Cormie P

    更新日期：2020-08-28 00:00:00

  • Does presence of prostate cancer affect serum testosterone levels in clinically localized prostate cancer patients?

    abstract：:The relationships between serum level of testosterone (T) and prostate cancer (PCa) are complex. The present study evaluated whether presence of PCa alters serum T levels. Subjects were 125 patients with clinically localized PCa treated using radical prostatectomy (RP), for whom pretreatment T levels were recorded. We...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2008.35

    authors： Imamoto T,Suzuki H,Yano M,Kawamura K,Kamiya N,Araki K,Komiya A,Naya Y,Shiraishi T,Ichikawa T

    更新日期：2009-01-01 00:00:00

  • The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting.

    abstract：INTRODUCTION:Multidisciplinary team (MDT) meetings use precise prognostic factors to select treatment options for patients with prostate cancer. Comorbidity is judged subjectively. Recent publications favour the Charlson comorbidity score (CS) for the use in the management of prostate cancer. We assess the feasibility ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500889

    authors： Kastner C,Armitage J,Kimble A,Rawal J,Carter PG,Venn S

    更新日期：2006-01-01 00:00:00

  • Potential of intermittent hormone therapy for M+ and M0 prostate cancer patients.

    abstract：:Increasingly animal and clinical studies suggest that intermittent therapy may improve the duration of hormone dependence in patients with prostate cancer. However there remains uncertainty as to optimal duration of treatment and level of prostate-specific antigen (PSA) before treatment is restarted. The aim of this s...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500483

    authors： Oliver RT,Farrugia D,Ansell W,Williams G,Chinegwundoh F

    更新日期：2000-12-01 00:00:00

  • Prostate cancer outcomes among older men: insurance status comparisons results from CaPSURE database.

    abstract：:With growing number of older adults in the United States and complexity of issues related to Medicare and other insurances more research is needed to evaluate an effectiveness of the different insurance types in prevention, screening and treatment of cancer. With prostate cancer being highly prevalent disease in older...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4501015

    authors： Sadetsky N,Elkin EP,Latini DM,DuChane J,Carroll PR,CaPSURE Investigators.

    更新日期：2008-01-01 00:00:00

  • Effects of androgen suppression and radiation on prostate cancer suggest a role for angiogenesis blockade.

    abstract：:Antiandrogen therapy is an important modality in the treatment of prostate cancer. Recent research into the role of angiogenesis in tumour growth and metastasis has uncovered links between antiandrogen therapy, radiation therapy and angiogenesis, which have exciting implications for the treatment of prostate cancer. A...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/sj.pcan.4500779

    authors： Woodward WA,Wachsberger P,Burd R,Dicker AP

    更新日期：2005-01-01 00:00:00

  • Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer.

    abstract：:We conducted a study in order to characterize changes after withdrawal of androgen ablation (AA) for prostate cancer. AA was withdrawn in 38 Japanese patients with prostate cancer who had undergone this therapy for various periods. Patients were stratified into those who had undergone AA for less than 24 months (Group...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.pcan.4500675

    authors： Egawa S,Okusa H,Matsumoto K,Suyama K,Baba S

    更新日期：2003-01-01 00:00:00

  • 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.

    abstract：:This literature review discusses the theoretical background of 5alpha-reductase inhibitor (5ARI) treatment and the resulting clinical implications. A Medline-based search for peer-reviewed articles addressing 5ARIs, benign prostatic hyperplasia and prostate cancer was performed. The 5ARIs Finasteride and Dutasteride, ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/pcan.2008.56

    authors： Dörsam J,Altwein J

    更新日期：2009-01-01 00:00:00

  • Magnetic resonance imaging in prostate cancer.

    abstract：:With the recently published National Institute of Clinical Excellence guidelines, it is now generally accepted that magnetic resonance imaging (MRI) is the imaging method of choice for staging prostate cancer in patients for whom radical treatment is being considered. MRI offers the single most accurate assessment of ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/sj.pcan.4500767

    authors： Heenan SD

    更新日期：2004-01-01 00:00:00

  • Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy.

    abstract：BACKGROUND:Intermittent androgen deprivation (IAD) for prostate cancer was studied with the objective of reducing the side effects of treatment and potentially delaying the development of hormone resistance. There also appears to be a quality of life benefit during off-treatment intervals owing to the recovery of serum...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1038/pcan.2012.12

    authors： Tunn UW,Canepa G,Kochanowsky A,Kienle E

    更新日期：2012-09-01 00:00:00

  • Primary care physician practices in the diagnosis, treatment and management of men with chronic prostatitis/chronic pelvic pain syndrome.

    abstract：:To describe practice patterns of primary care physicians (PCPs) for the diagnosis, treatment and management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), we surveyed 556 PCPs in Boston, Chicago, and Los Angeles (RR=52%). Only 62% reported ever seeing a patient like the one described in the vignette. I...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2009.9

    authors： Calhoun EA,Clemens JQ,Litwin MS,Walker-Corkery E,Markossian T,Kusek JW,McNaughton-Collins M

    更新日期：2009-01-01 00:00:00

  • Practice patterns of primary EBRT with and without ADT in prostate cancer treatment.

    abstract：BACKGROUND:Androgen deprivation therapy (ADT) has been shown to improve survival for men with intermediate and high-risk prostate cancer undergoing external-beam radiation therapy (EBRT). Using data from a community-based prospective disease registry, we investigated usage of EBRT with or without neoadjuvant ADT. METH...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-018-0084-3

    authors： Schmidt B,Eapen RS,Cowan JE,Broering JM,Greene KL,Carroll PR,Cooperberg MR

    更新日期：2019-03-01 00:00:00

  • Fatigue in hormone-naïve prostate cancer patients treated with radical prostatectomy or definitive radiotherapy.

    abstract：:Chronic fatigue (CF) is a distressing symptom that follows cancer treatment; however, it has rarely been studied in hormone-naïve prostate cancer survivors after radical prostatectomy (RP) or definitive radiotherapy (RAD). We investigated CF in prostate cancer survivors after RP or RAD as monotherapy and explored asso...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2009.61

    authors： Kyrdalen AE,Dahl AA,Hernes E,Cvancarova M,Fosså SD

    更新日期：2010-06-01 00:00:00

  • Nationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America project.

    abstract：BACKGROUND:Several treatment options for clinically localized prostate cancer currently exist under the established guidelines. We aim to assess nationally representative trends in treatment over time and determine potential geographic variation using two large national claims registries. METHODS:Men with prostate can...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2015.3

    authors： Cary KC,Punnen S,Odisho AY,Litwin MS,Saigal CS,Cooperberg MR,NIDDK Urologic Diseases in America Project.

    更新日期：2015-06-01 00:00:00

  • A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.

    abstract：BACKGROUND:Intermittent androgen suppression (IAS) is an increasingly popular treatment option for castrate-sensitive prostate cancer. On the basis of previous data with anti-angiogenic strategies, we hypothesized that pan-inhibition of the vascular endothelial growth factor receptor using pazopanib during the IAS off ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1038/pcan.2011.49

    authors： Ward JE,Karrison T,Chatta G,Hussain M,Shevrin D,Szmulewitz RZ,O'Donnell PH,Stadler WM,Posadas EM

    更新日期：2012-03-01 00:00:00

  • Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.

    abstract：BACKGROUND:Patients with high-risk prostate cancer have an increased likelihood of experiencing a relapse following radical prostatectomy (RP). We previously conducted three neoadjuvant androgen-deprivation therapy (ADT) trials prior to RP in unfavorable intermediate and high-risk disease. METHODS:In this analysis, we...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-017-0009-6

    authors： McKay RR,Montgomery B,Xie W,Zhang Z,Bubley GJ,Lin DW,Preston MA,Trinh QD,Chang P,Wagner AA,Mostaghel EA,Kantoff PW,Nelson PS,Kibel AS,Taplin ME

    更新日期：2018-09-01 00:00:00

  • The potential role of bisphosphonates in prostate cancer.

    abstract：:Skeletal morbidity secondary to metastases and osteoporosis is common in patients with advanced prostate cancer. Despite the typically sclerotic nature of prostate cancer metastases, osteoclast mediated osteolysis may play a significant role. This review addresses the newly recognised antitumour effects of bisphosphon...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/sj.pcan.4500607

    authors： Oades GM,Coxon J,Colston KW

    更新日期：2002-01-01 00:00:00

  • Associations among statins, preventive care, and prostate cancer mortality.

    abstract：BACKGROUND:Increasing evidence indicates an association between statins and reduced prostate cancer-specific mortality (PCSM). However, significant bias may exist in these studies. One particularly challenging bias to assess is the healthy user effect, which may be quantified by screening patterns. We aimed to evaluate...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-020-0207-5

    authors： Kumar A,Riviere P,Luterstein E,Nalawade V,Vitzthum L,Sarkar RR,Bryant AK,Einck JP,Mundt AJ,Murphy JD,Rose BS

    更新日期：2020-09-01 00:00:00

  • Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases.

    abstract：BACKGROUND:In an era of multiple life-prolonging therapies for metastatic castration resistant prostate cancer (mCRPC), the optimal timing of initiation and duration of antiresorptive bone targeted therapy (BTT) to prevent skeletal related events (SREs) is unknown. METHODS:To assess practice patterns of BTT use and it...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-020-00280-6

    authors： McGregor B,Zhang L,Gray KP,Shaw G,Evan C,Francini E,Sweeney C

    更新日期：2020-09-03 00:00:00

  • A prospective clinical trial of HIFU hemiablation for clinically localized prostate cancer.

    abstract：BACKGROUND:Focal therapy is an emerging mini-invasive treatment modality for localized prostate cancer aimed to reduce the morbidity associated with radical therapy while maintaining optimal cancer control. We report the mid-term oncological and functional results of primary hemiablation high-intensity focused ultrasou...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 临床试验,杂志文章

    doi：10.1038/pcan.2015.55

    authors： van Velthoven R,Aoun F,Marcelis Q,Albisinni S,Zanaty M,Lemort M,Peltier A,Limani K

    更新日期：2016-03-01 00:00:00

  • Invasion of bladder neck after radical prostatectomy: one definition for different outcomes.

    abstract：:The aim of the study was to evaluate factors of progression after radical prostatectomy in patients with bladder neck invasion (BNI). From 1988 to 2006, 1395 patients underwent radical prostatectomy, 120 (8.6%) had microscopic BNI (pT4 N0, TNM 2002). Group 1 was defined as BNI alone, group 2 as BNI plus extracapsular ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4501009

    authors： Rodriguez-Covarrubias F,Larré S,Dahan M,De La Taille A,Allory Y,Yiou R,Vordos D,Hoznek A,Abbou CC,Salomon L

    更新日期：2008-01-01 00:00:00

  • The role of candidate genetic polymorphisms in the etiology of prostate cancer.

    abstract：:Prostate cancer appears to result from complex interactions among genetic, endocrine and environmental factors. Identification of risk factors for development and progression of prostate cancer is needed. This will allow researchers to design strategies to reduce the morbidity and mortality from this cancer and to ide...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500471

    authors： Neuhausen SL

    更新日期：2000-12-01 00:00:00

  • High level of dioxin-TEQ in tissue is associated with Agent Orange exposure but not with biochemical recurrence after radical prostatectomy.

    abstract：BACKGROUND:Agent Orange (AO) was previously identified as a significant risk factor for biochemical recurrence (BCR) after radical prostatectomy (RP) in prostate cancer patients. In this study, we determined the levels of dioxin biological toxicity using toxic equivalency (TEQ) values and examined the impact of dioxin-...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2013.33

    authors： Li Q,Lan L,Klaassen Z,Shah SR,Moses KA,Terris MK

    更新日期：2013-12-01 00:00:00

  • The role of external radiotherapy in patients treated with permanent prostate brachytherapy.

    abstract：:To examine the difference in Prostate Specific Antigen (PSA)-Relapse Free Survival (RFS) in patients (pts) with prostate cancer treated with permanent prostate brachytherapy (PPB) alone (monotherapy) or combined modality PPB and external radiotherapy (CMT) by a matched pair analysis. There were 1476 pts who were treat...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/sj.pcan.4500552

    authors： Potters L,Fearn P,Kattan M

    更新日期：2002-01-01 00:00:00

  • The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer.

    abstract：:The purpose of this study was to evaluate the relationship of baseline body mass index (BMI) and serum testosterone level with prostate cancer outcomes in men with castration-resistant metastatic prostate cancer (CRPC). BMI and testosterone levels were evaluated for their ability to predict overall survival (OS) and p...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2008.36

    authors： Armstrong AJ,Halabi S,de Wit R,Tannock IF,Eisenberger M

    更新日期：2009-01-01 00:00:00

  • Impact of body mass index on clinicopathological outcome and biochemical recurrence after radical prostatectomy.

    abstract：BACKGROUND:Accumulating evidence suggests that obesity is associated with tumor progression in prostate cancer (PCa) patients after radical prostatectomy (RP). We conducted a retrospective multicenter study to determine the effect of body mass index (BMI) on the clinicopathological characteristics and biochemical recur...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,多中心研究

    doi：10.1038/pcan.2013.16

    authors： Narita S,Mitsuzuka K,Yoneyama T,Tsuchiya N,Koie T,Kakoi N,Kawamura S,Kaiho Y,Ohyama C,Tochigi T,Yamaguchi T,Habuchi T,Arai Y

    更新日期：2013-09-01 00:00:00

  • Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer.

    abstract：BACKGROUND:Patients with prostate cancer are at risk of impaired bone health. Prostate cancer has a propensity to metastasize to bone, after which patients are at risk of skeletal-related events (SREs). These complications are associated with increased mortality, substantial pain, and reduced quality of life. Patients ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-018-0060-y

    authors： Miller K,Steger GG,Niepel D,Lüftner D

    更新日期：2018-11-01 00:00:00

  • Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis.

    abstract：:The purpose of this study was to identify the early predictor of survival for prostate cancer patients with bone metastasis. We reviewed 87 prostate cancer patients with bone metastasis who had received primary androgen deprivation therapy (PADT) at our institution. The medical records of the patients were examined wi...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2011.14

    authors： Sasaki T,Onishi T,Hoshina A

    更新日期：2011-09-01 00:00:00

  • ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodies.

    abstract：BACKGROUND:Overexpression of the ERG protein is highly prevalent in prostate cancer (PCa) and commonly results from gene fusions involving the ERG gene. Recently, N-terminal epitope-targeted mouse and a C-terminal epitope-targeted rabbit monoclonal anti-ERG antibody (ERG-MAbs) have been introduced for the detection of ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2011.67

    authors： Braun M,Goltz D,Shaikhibrahim Z,Vogel W,Böhm D,Scheble V,Sotlar K,Fend F,Tan SH,Dobi A,Kristiansen G,Wernert N,Perner S

    更新日期：2012-06-01 00:00:00

  • Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy.

    abstract：:It has been suggested that in multifocal prostate cancer (PCa), focal therapy to the largest (index) lesion is sufficient, because secondary non-index lesions are unlikely to contribute to disease progression. In this study, the role of PCa focality in selecting men for focal therapy was evaluated. A histopathological...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2010.16

    authors： Karavitakis M,Winkler M,Abel P,Livni N,Beckley I,Ahmed HU

    更新日期：2011-03-01 00:00:00